Company Overview
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +30.38% |
| 6 Months: | -21.37% |
| 3 Months: | -19.69% |
| 1 Month: | +5.64% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.79 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 45.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TARA Protara Therapeutics, Inc. R2K | 4.12 | -3.03 | $231.56M | 0.00% | -32.51% | -37.27% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 2.95M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -1.91M | - | -1.93M | -2.51M | 134.00K | - | -4.62M | -4.98M | -5.08M | -6.82M | -7.85M | -7.17M | -6.48M | -5.99M | -12.31M | -6.37M | -5.00M | -4.62M | -1.53M | -1.43M | -2.35M | -10.16M | -7.27M | -8.06M | -13.58M | -12.79M | -10.83M | -10.87M | -8.71M | -7.97M | -9.73M | -12.14M | -10.70M | -11.85M | -10.66M | -12.33M | -14.12M | -16.59M | -14.76M | -19.63M |
| Net Income | -2.10M | -2.40M | -2.83M | -2.56M | -5.18M | 7.23M | -4.58M | -5.07M | -5.38M | -6.55M | -7.91M | -7.11M | -6.50M | -5.61M | -12.31M | -6.08M | -4.88M | -4.51M | -1.53M | -1.43M | -2.35M | -10.06M | -7.14M | -7.97M | -13.46M | -12.78M | -10.78M | -10.76M | -8.54M | -7.69M | -9.04M | -11.29M | -9.86M | -11.10M | -9.51M | -11.22M | -11.91M | -14.96M | -13.26M | -17.78M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.14 | -0.96 | -0.96 | -0.76 | -0.68 | -0.80 | -1.00 | -0.87 | -0.97 | -0.45 | -0.50 | -0.29 | -0.35 | -0.31 | -0.31 |
| R&D Expense | 971.00K | - | 1.19M | 1.60M | 1.77M | - | 2.63M | 3.09M | 3.08M | 4.35M | 5.24M | 4.84M | 4.25M | 3.89M | 10.34M | 4.07M | 2.76M | 2.35M | 1.08M | 986.72K | 1.10M | 3.06M | 2.47M | 2.80M | 7.04M | 5.89M | 4.09M | 5.27M | 3.08M | 3.47M | 5.14M | 7.25M | 6.22M | 7.75M | 6.39M | 8.07M | 9.15M | 10.77M | 9.59M | 13.56M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 2.95M | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -8.00M | -7.12M | -7.58M | -20.87M | -28.70M | -30.36M | -21.37M | -7.83M | -34.44M | -47.49M | -67.06M | -43.61M | -49.15M | -64.55M |
| Net Income | -7.97M | -7.91M | -3.34M | -21.38M | -28.53M | -29.96M | -20.73M | -7.83M | -33.98M | -47.25M | -65.95M | -40.42M | -44.60M | -57.44M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -4.21 | -5.86 | -3.57 | -2.17 | -1.34 |
| R&D Expense | 5.91M | 3.99M | 6.43M | 12.38M | 18.87M | 21.69M | 11.85M | 3.88M | 11.98M | 21.09M | 16.81M | 24.99M | 31.70M | 42.63M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 5.66M | 84.80M | 67.54M | 43.52M | 43.98M | 23.52M | 1.22M | 203.16M | 172.60M | 113.29M | 78.95M | 181.45M | 209.47M |
| Total Equity | -72.66M | -86.66M | -100.51M | 82.46M | 63.41M | 38.44M | 34.74M | 4.78M | -2.13M | 199.24M | 161.91M | 102.08M | 68.32M | 167.13M | 196.41M |
| Cash & Equivalents | 3.27M | 2.41M | 2.79M | 68.84M | 40.03M | 36.39M | 21.17M | 19.37M | 564.00K | 168.60M | 35.72M | 24.13M | 39.59M | 162.80M | 49.66M |
| Total Liabilities | - | - | 9.77M | 2.34M | 4.13M | 5.08M | 9.24M | 3.08M | 3.35M | 3.91M | 10.68M | 11.21M | 10.63M | 14.32M | 13.06M |
| Current Liabilities | - | - | 9.77M | 2.34M | 4.13M | 5.08M | 9.24M | 3.08M | 3.35M | 2.92M | 4.30M | 5.74M | 6.15M | 10.96M | 10.94M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -17.57M | -23.69M | -22.35M | -23.23M | -5.01M | -23.41M | -34.50M | -26.46M | -37.56M | -35.81M | -56.37M |
| Investing Cash Flow | - | - | - | -11.33M | 19.92M | -16.10M | 18.43M | -475.00K | 2.83M | -98.19M | 14.95M | 53.11M | 19.16M | -139.49M |
| Financing Cash Flow | - | - | - | 163.00K | 208.00K | 23.05M | 2.98M | 500.00K | 189.40M | -228.00K | -90.00K | -91.00K | 139.87M | 82.72M |
| Capital Expenditure | -67.00K | -10.00K | -51.00K | -198.00K | -271.00K | -35.00K | -119.00K | -475.00K | -884.00K | -596.00K | -120.00K | -45.00K | -63.00K | -94.00K |
| Free Cash Flow | - | - | - | -17.76M | -23.96M | -22.39M | -23.35M | -5.49M | -24.29M | -35.10M | -26.58M | -37.60M | -35.87M | -56.46M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | 228.00K | 90.00K | 91.00K | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -257.1% | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | -113.4% | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 9.2% | 7.9% | -4.1% | -33.7% | -74.2% | -86.3% | -433.8% | 368.0% | -17.1% | -29.2% | -64.6% | -59.2% | -26.7% | -29.2% |
| ROCE % | - | 173.3% | -9.2% | -32.9% | -74.7% | -87.4% | -104.5% | 368.0% | -17.2% | -28.2% | -62.4% | -59.9% | -28.8% | -32.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Janus Henderson Group PLC | 9.26% | 5.21M | $21.53M |
| 2 | Blackrock Inc. | 6.04% | 3.39M | $14.04M |
| 3 | Velan Capital Investment Management LP | 5.04% | 2.83M | $11.72M |
| 4 | Millennium Management Llc | 5.04% | 2.83M | $11.71M |
| 5 | Blackstone Inc | 4.03% | 2.27M | $9.37M |
| 6 | Vanguard Capital Management LLC | 3.77% | 2.12M | $8.76M |
| 7 | Sio Capital Management, LLC | 3.50% | 1.97M | $8.15M |
| 8 | Acorn Capital Advisors, LLC | 3.12% | 1.75M | $7.24M |
| 9 | Integral Health Asset Management, LLC | 3.11% | 1.75M | $7.24M |
| 10 | AIGH Capital Management LLC | 2.89% | 1.62M | $6.71M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TARA
TARA — Frequently Asked Questions
What is the current share price of Protara Therapeutics, Inc. (TARA)?
As of 2026-07-15 16:51 PDT, Protara Therapeutics, Inc. (TARA) trades at $4.12 on NasdaqGM. Its 52-week range is $3.03 to $7.56.
What is the market capitalisation of TARA?
Protara Therapeutics, Inc. (TARA) has a market capitalisation of $231.56M on NasdaqGM.
What is the P/E ratio of TARA?
TARA trades at a trailing price-to-earnings (P/E) ratio of -3.03. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 1.26.
What is the return on equity (ROE) of TARA?
TARA has a return on equity (ROE) of -37.27%. Its return on capital employed (ROCE) is -32.51%.
Is TARA a good stock to buy?
This page provides a data-driven analysis of Protara Therapeutics, Inc. (TARA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.